Drug-induced Ototoxicity: Mechanisms and Otoprotective Strategies
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 26880
Special Issue Editors
Interests: ototoxicity; cochleotoxicity; aminoglycosides; inflammatory responses; blood–labyrinth barrier; drug screening; drug delivery; pharmacokinetics and pharmacodynamics of ototoxic and otoprotection drugs; ex vivo and in vivo animal models for testing hearing
Interests: hair cell regeneration; cell cycle manipulation; regenerative strategies; otoprotection; ototoxicity; drug screening; drug development; pharmacological interventions
Interests: ototoxicity; otoprotective strategies; antimicrobials; medicinal chemistry; drug discovery/development; pharmacokinetics
Interests: hearing loss; chemotherapy- and noise-induced hearing loss; drug screenings; drug development; repurposing drugs for hearing protection; drug delivery; combination therapies; anti-apoptotic drugs including kinase inhibitors; anti-cancer and anti-inflammatory agents; ex vivo and in vivo models for testing hearing; cellular mechanisms of otoprotection; role of the supporting cells in otoprotection
Special Issue Information
Dear Colleagues,
Cells within the inner ear are protected by the blood–labyrinth barrier (BLB; endothelial cells of the inner ear vasculature) and by the epithelial cells lining the endolymphatic duct. In homeostatic conditions, this strict permeability barrier is required to maintain the electrophysiological environment that enables sensitive auditory and vestibular functions. However, in circumstances that require therapeutic interventions for otoprotection or repair of inner ear structures, the permeability of the BLB becomes a significant challenge. For example, while clinically essential, yet cochleotoxic and vestibulotoxic, aminoglycosides and cisplatin readily cross the BLB, but other compounds intended to maintain or protect the inner ear may be unable to do so. Furthermore, preclinical models that facilitate the discovery of otoprotective compounds and mimic the medical settings in which ototoxicity occurs to validate and optimize candidate ototprotective compounds are critically required. For this special issue, we invite original research and review manuscripts in two broad categories:
(i) Mechanisms of ototoxicity, including but not limited to transport of ototoxins across the blood–labyrinth barrier, including anatomy and physiology; paracellular, expression, and kinetics of drug-permeant ion channels and transporters for uptake and elimination of ototoxins, pharmacokinetics and pharmacodynamics within the inner ear, inner ear intracellular signalling pathways, development of preclinical of clinical settings where ototoxicity is prevalent, modulation by comorbidities (e.g., aging, inflammation, injury, ischemia, neurodegenerative disease, noise trauma), genetic polymorphisms, and dysfunction;
(ii) Strategies for otoprotection, including but not limited to drug discovery, drug screening, drug–response curves, dosage strategies, local and systemic drug delivery and clearance of otoprotective compounds from the inner ear, balance of drug toxicities to therapeutic benefits, challenges related to the delivery of gene therapies, nanotechnologies, biologics, or small molecules, drug repurposing, structure–activity relationships in developing and testing otoprotective drugs, preclinical models for testing efficacy of otoprotective drugs in clinically relevant settings, and role of supporting cells in otoprotection of sensory hair cells.
Ultimately, all manuscripts should focus on the translational aspects of developing drugs, other genetic and biomedical strategies for preserving sensory hair cells within the inner ear with putative high clinical/translational impact, and/or the cellular mechanism(s) by which these drugs/strategies work during/after exposure to ototoxic drugs. All manuscripts should also discuss gaps in knowledge for that specific topic that need to be addressed.
Prof. Peter S. Steyger
Prof. Sonia M. Rocha-Sanchez
Dr. E. Jeffrey North
Dr. Tal Teitz
Guest Editors
Keywords
- Ototoxicity
- Cochleotoxicity
- Vestibulotoxicity
- Ototoxins
- Aminoglycosides
- Cisplatin
- Noise
- Inflammatory responses
- Otoprotective compounds
- Blood–labyrinth barrier
- Blood–labyrinth barrier permeability
- Drug delivery to the inner ear
- Drug screening
- Drug development
- Repurposing drugs
- Anti-cancer drugs
- Animal models for testing ototoxicity
- Sensory cells of the inner ear
- Supporting cells of the inner ear
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
